- Associated Press - Monday, July 30, 2012

GENEVA (AP) - Swiss drug maker Novartis AG says it has received European approval to market Afinitor for treatment of women with the most common form of advanced breast cancer.

Afinitor is already approved to treat various tumors of the pancreas, kidney and brain.

The U.S. Food and Drug Administration approved the pill-based drug earlier this month for use in combination with Aromasin for postmenopausal women with recurring hormone receptor positive breast cancer lacking the protein HER2.

Novartis said Monday that the European Commission’s approval was based on a trial of more than 700 patients showing those treated with the two drugs lived significantly longer before their disease progressed.

The company said recently its annual sales of Afinitor could rise above the $1 billion mark with the new approvals.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide